Recce's R327 found effective against E.coli during clinical trial
Recce Pharmaceuticals Ltd has found that its R327 drugs is effective in treating Escherichia coli during a Phase I/II clinical trial.
T1G
0.00%
0.0¢
![](/images/icons/chart-icon.png)
Tiger Tasman Minerals Limited - TBA - Announcements
Currently unlisted.
Proposed listing date: TBA
Add to my watchlist